Related Experiment Video

Updated: Aug 16, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients

A Asberg1, A Hartmann, E Fjeldså

  • 1Medical Department, The National Hospital, Oslo, Norway. anderas@klinmed.uio.no

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
|July 9, 2002
PubMed

Insights

This study examined the interaction between atorvastatin and cyclosporine A (CsA) in kidney transplant patients. Atorvastatin increased CsA

Area of Science:

  • Pharmacology
  • Nephrology
  • Immunosuppression

Background:

  • Atorvastatin is commonly prescribed for cholesterol management in organ transplant recipients on cyclosporine A (CsA).
  • The pharmacokinetic interaction between atorvastatin and CsA in renal transplant recipients remains largely uncharacterized.

Purpose of the Study:

  • To investigate the bilateral pharmacokinetic interaction between atorvastatin and CsA in renal transplant recipients.
  • To assess the impact of atorvastatin on CsA exposure and lipid levels.

Main Methods:

  • A pharmacokinetic study was conducted in 21 renal transplant recipients over 4 weeks.
  • Patients received atorvastatin (10 mg/day) alongside their standard CsA and prednisolone immunosuppression.
  • Cyclosporine A (CsA) and atorvastatin pharmacokinetics were measured at baseline and after 4 weeks of atorvastatin treatment.

Main Results:

  • Atorvastatin treatment led to a sixfold increase in plasma HMG-CoA reductase inhibitory activity in CsA-treated patients.
  • Atorvastatin moderately reduced CsA's area under the curve (AUC0-12) by 9.5% and Cmax by 13.5%.
  • Total cholesterol and LDL cholesterol significantly decreased by 26.8% and 41.5%, respectively.

Conclusions:

  • A significant bilateral pharmacokinetic interaction exists between atorvastatin and CsA in renal transplant recipients.
  • While atorvastatin enhances CsA's inhibitory activity, its effect on CsA systemic exposure is moderate.
  • Atorvastatin effectively reduces cholesterol levels in this patient population.

More Related Videos

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model10:31

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model

Published on: August 13, 2017

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Related Concept Videos

Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions01:09

Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions

Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...